News

Test your knowledge on approved biologics in the management of moderate to severe atopic dermatitis and considerations for an 18-year-old man's case.

ICYMI, this week we had articles about World Psoriasis Day, the FDA approval of secukinumab for hidradenitis suppurativa, positive data of delgocitinib cream for chronic hand eczema, and more.

Polyphenols, found in certain foods, have antioxidant and anti-inflammatory properties may help modulate immune responses, offering potential adjunctive therapy for atopic dermatitis, psoriasis, and chronic urticaria.

The Sun Pharma survey included 1003 respondents with mild to moderate acne.

PASI scores were significantly correlated with sleep quality, duration, and disturbances.

Investigators believe different circulating inflammatory phenotypes in patients with vitiligo may influence their responses to treatment with ruxolitinib cream.

Delgocitinib is first-in-class pan-Janus kinase inhibitor.

The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Authors of the case report that little is known about the associations between psoriasis and renal function.

Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.

Click here to answer this week's skin cancer poll.

Additionally, investigators found that several patients in the review had rosacea induced or exacerbated by the use of topical corticosteroids on the face.

In this week’s Pointers With Portela, the 208SkinDoc explains the hidden risks associated with hair transplants.

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.

A comparative study revealed that color constancy algorithms reduce the variability of dermoscopy image quality, leading to positive outcomes for practitioners.

Learn more about the in-depth topics covered in the October 2023 print issue of Dermatology Times.

Secukinumab is currently the only IL-17A inhibitor approved for the condition.

From reducing age spots to nurturing the lip microbiome and supporting sensitive skin, 3 studies presented at the 2023 Integrative Dermatology Symposium highlighted the transformative potential of botanicals in skincare.

A new AI platform empowers health care practitioners in numerous specialties to make informed decisions and provide high-quality care to patients with scabies.

If you weren’t able to attend the 2023 Society of Dermatology Physicians Fall Conference or want to review our latest coverage and interviews, our full recap has you covered.

Click here to answer today's poll.

Review the full list of eczema resources for your patients shared during National Eczema Awareness Month.

Catch up on coverage from the fourth and final day of the 2023 SDPA Fall Dermatology Conference.

Allison Arthur, MD, discussed the importance of tailoring a treatment plan for adult women with acne vulgaris that best suits their lifestyle and current needs.

Mark Lebwohl, MD, spoke with Dermatology Times about his talk on IL-17 inhibitors.

Ted Rosen, MD, presented a session comprehensively discussing common dermatoses characterized by itch and pruritus.

The study was presented in a poster at the 2023 SDPA Fall Conference in Nashville, TN.

Leah Howard, JD, of the National Psoriasis Foundation, discusses the importance of advocacy in psoriasis, the role of mental health in chronic skin conditions, and the role of support organizations in advocating for awareness and health equity.

Catch up on coverage from the third day of the 2023 SDPA Fall Dermatology Conference.